Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.

Literature DB >> 29380516

Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.

Asher M Marks¹, Ranjit S Bindra², Michael L DiLuna³, Anita Huttner⁴, Vikram Jairam², Kristopher T Kahle⁵, Mark W Kieran⁶.

Abstract

Efficacy of BRAF V600E targeted therapies in brain tumors harboring the mutation has been shown in several case reports and is currently being studied in larger clinical trials. Monotherapy with vemurafenib has been associated with significant side effects, including rashes, papillomas, and squamous cell carcinomas. Here we describe an adolescent female with anaplastic ganglioglioma and significant skin reaction to vemurafenib with subsequent tumor response and tolerance to the BRAF/MEK inhibitor combination of dabrafenib and trametinib without recurrence of previous reaction.

Entities: Chemical Disease Gene Mutation

Keywords: AYA; BRAF V600E; BRAF inhibitor; CNS tumor; MEK inhibitor; ganglioglioma

Mesh：

Substances：

Year: 2018 PMID： 29380516 DOI： 10.1002/pbc.26969

Source DB: PubMed Journal: Pediatr Blood Cancer ISSN： 1545-5009 Impact factor: 3.167

Keyword Cloud
Cited

11 in total

1. Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.

Authors: Francesco Pasqualetti; Giuliana Restante; Alessandra Gonnelli; Eleonora Rofi; Alessandro Molinari; Stefania Crucitta; Fabiola Paiar; Roberta Rudà; Romano Danesi; Riccardo Soffietti; Marzia Del Re
Journal: Neuro Oncol Date: 2019-12-17 Impact factor: 12.300

2. Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?

Authors: Marco Crocco; Antonio Verrico; Claudia Milanaccio; Gianluca Piccolo; Patrizia De Marco; Gabriele Gaggero; Valentina Iurilli; Sonia Di Profio; Federica Malerba; Marta Panciroli; Paolo Giordano; Maria Grazia Calevo; Emilio Casalini; Natascia Di Iorgi; Maria Luisa Garrè
Journal: Cancers (Basel) Date: 2022-05-29 Impact factor: 6.575

3. Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm.

Authors: Adam Kowalewski; Justyna Durślewicz; Marek Zdrenka; Dariusz Grzanka; Łukasz Szylberg
Journal: Target Oncol Date: 2020-08 Impact factor: 4.493

4. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.

Authors: R Borrill; E Cheesman; S Stivaros; I D Kamaly-Asl; K Gnanalingham; John-Paul Kilday
Journal: Childs Nerv Syst Date: 2018-08-01 Impact factor: 1.475

5. Sustained response of three pediatric BRAF^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy.

Authors: Stephanie A Toll; Hung N Tran; Robert Cooper; Ashley S Margol; Jennifer Cotter; Alexander R Judkins; Benita Tamrazi; Jaclyn A Biegel; Girish Dhall; Nathan J Robison; Kaaren Waters; Palak Patel
Journal: Oncotarget Date: 2019-01-11

Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.

1. Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.

2. Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?

3. Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm.

4. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.

5. Sustained response of three pediatric BRAF^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy.

Review 6. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.

Review 7. Oncogenic BRAF Alterations and Their Role in Brain Tumors.

Review 8. Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.

Review 9. New Approaches with Precision Medicine in Adult Brain Tumors.

10. Dual inhibition of BRAF and mTOR in BRAF ^V600E -mutant pediatric, adolescent, and young adult brain tumors.

Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.

1. Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.

2. Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?

3. Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm.

4. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.

5. Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy.

Review 6. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.

Review 7. Oncogenic BRAF Alterations and Their Role in Brain Tumors.

Review 8. Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.

Review 9. New Approaches with Precision Medicine in Adult Brain Tumors.

10. Dual inhibition of BRAF and mTOR in BRAF V600E -mutant pediatric, adolescent, and young adult brain tumors.

5. Sustained response of three pediatric BRAF^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy.

10. Dual inhibition of BRAF and mTOR in BRAF ^V600E -mutant pediatric, adolescent, and young adult brain tumors.